View on GitHub
Revised entries:
- (FDA) KRAS p.G12C and sensitivity to sotorasib’s description was revised to remove underscores.
- (Preclinical) KRAS somatic variants and sensitivity to FGFR1 inhibitor + trametinib was revised to remove a trailing space from the therapy name.